CRIS - キュ―リス (Curis Inc.) キュ―リス



symbol CRIS
会社名 Curis Inc (キュ―リス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 キュリス(Curis Inc.)は癌治療薬の開発、商業化を求めるバイオテクノロジー企業である。同社の薬品候補は経口可能なヒストン脱アセチル化酵素(HDAC)の小分子阻害剤CUDC-907、ホスファチジルイノシトール-3-キナーゼ(PI3K)酵素を含む。CUDC-907はクラスI、IIのHDAC、及びクラスIのPI3K酵素の経口二重阻害剤である。CA-170は免疫活性化の負の調節因子として独立して機能するプログラムされた死亡リガンド-1(PDL1)およびT細胞活性化のVドメインIgサプレッサー(VISTA)免疫チェックポイントタンパク質を選択的に標的化するために設計される経口小分子薬物候補である。CA-4948はトール様受容体またはある種のインターロイキン受容体シグナル伝達経路のトランスデューサであるインターロイキン-1受容体関連キナーゼ4(IRAK4)キナーゼを阻害するために設計される経口小分子薬物候補である。   キュ―リスは、癌治療の研究開発に従事する米国企業。社内および共同で研究開発プログラムを行っている。癌薬剤候補は、リンパ腫および多発性骨髄腫治療の「CUDC-907」、固形腫瘍およびリンパ腫治療の「CUDC-427」、高度な基底細胞癌の治療のために承認された薬「Erivedge」がある。   Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination the with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
本社所在地 4 Maguire Road Lexington MA 02421 USA
代表者氏名 James R. McNab ジェームズ・R・マクナブ
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-503-6500
設立年月日 36557
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 55人
EBITDA EBITDA(百万ドル) -39.14600
終値(lastsale) 1.92
時価総額(marketcap) 63707800.32
時価総額 時価総額(百万ドル) 65.03505
売上高 売上高(百万ドル) 10.53200
企業価値(EV) 企業価値(EV)(百万ドル) 63.11205
当期純利益 当期純利益(百万ドル) -42.89600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Curis Inc. revenues increased 15% to $4.8M. Net loss decreased 35% to $19.4M. Revenues reflect Royalties increase of 13% to $4.9M Research and development net increase of 58% to -$42K. Lower net loss reflects Research_development Expenses B/F decrease of 42% to $13.9M (expense) Stock-Based Compensation Expense in SGA decrease of 21% to $1.6M (expense).



   Analysts Say Curis Inc. (NASDAQ:CRIS) Can Really Get To $10.00 In 12 Months  2023/01/27 17:10:00 Marketing Sentinel
In recent trading session, Curis Inc. (NASDAQ:CRIS) saw 0.49 million shares changing hands at last check today with its beta currently measuring 2.89. Company’s recent per share price level of $0.76 trading at $0.0 or 0.91% at last check today assigns it a market valuation of $74.86M. That most recent trading price of CRIS’s stock … Analysts Say Curis Inc. (NASDAQ:CRIS) Can Really Get To $10.00 In 12 Months Read More »
   Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023 -  2023/01/27 14:51:00 Kwhen Finance
   Is The Stock A Good Investment? Curis, Inc. (NASDAQ:CRIS -0.21%), EVgo, Inc. (NASDAQ:EVGO -1.76%)  2023/01/25 12:26:59 Stock Equity
Curis, Inc. (NASDAQ:CRIS) with the stream of -0.21% also noticed, India EVgo, Inc. (NASDAQ:EVGO) encountered a rapid change of -1.76% in the last hour of Tuesday’s trading session. Curis, Inc. … The post Is The Stock A Good Investment? Curis, Inc. (NASDAQ:CRIS -0.21%), EVgo, Inc. (NASDAQ:EVGO -1.76%) appeared first on Stocks Equity .
   Curis Inc. (NASDAQ: CRIS) – Analysts’ Revisions Point To Positive Sentiment  2023/01/04 12:30:00 Stocks Register
Curis Inc. (NASDAQ:CRIS) traded at $0.62 at close of the session on Tuesday, 01/03/23, made an upward move of 12.02% on its previous day’s price. Looking at the stock we see that its previous close was $0.55 and the beta (5Y monthly) reads 2.72 with the day’s price range being $0.55 – $0.65. In terms … Curis Inc. (NASDAQ: CRIS) – Analysts’ Revisions Point To Positive Sentiment Read More »
   Do investors need to be concerned about Curis Inc. (CRIS)?  2023/01/03 13:32:00 US Post News
In Friday’s session, Curis Inc. (NASDAQ:CRIS) marked $0.55 per share, down from $0.56 in the previous session. While Curis Inc. has underperformed by -1.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRIS fell by -88.47%, with highs and lows ranging from $5.27 to $0.47, whereas […]
   Curis (CRIS) Q1 2022 Earnings Call Transcript  2022/05/06 05:01:00 The Motley Fool
CRIS earnings call for the period ending March 31, 2022.
   Curis Inc.''s (CRIS) CEO Jim Dentzer on Q1 2022 Results - Earnings Call Transcript  2022/05/05 22:55:21 Seeking Alpha
Curis, Inc. (NASDAQ:NASDAQ:CRIS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 P.M.
   Curis GAAP EPS of -$0.18 misses by $0.02, revenue of $2.06M misses by $0.49M  2022/05/05 20:10:40 Seeking Alpha
Curis press release (NASDAQ:CRIS): Q1 GAAP EPS of -$0.18 misses by $0.02.Revenue of $2.06M (-5.9% Y/Y) misses by $0.49M.Shares -2.2%.
   Curis Reports First Quarter 2022 Financial Results and Business Update  2022/05/05 20:01:00 investors Curis
   Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022  2022/04/28 20:00:00 investors Curis
   Marin Software, QuinStreet lead postmarket gainers; Annexon, Dogness among losers  2022/01/06 22:29:07 Seeking Alpha
Gainers: Marin Software MRIN +43%, QuinStreet (QNST) +5%, Axsome Therapeutics (AXSM) +4%, PRTS +3%, Curis CRIS +3%.Losers: Annexon (ANNX) -5%, Dogness (DOGZ) -4%,
   Curis provides update on phase 1/2 blood cancer study of CA-4948  2022/01/06 14:25:53 Seeking Alpha
   How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs?  2021/12/18 20:00:00 Marketing Sentinel
During the last session, Curis Inc. (NASDAQ:CRIS)s traded shares were 3.56 million, with the beta value of the company hitting 2.84. At the end of the trading day, the stocks price was $4.79, reflecting an intraday gain of 7.16% or $0.32. The 52-week high for the CRIS share is $17.40, that puts it down -263.26 How Could You Make A Quick Recovery From Curis Inc. (NASDAQ: CRIS) Given A -463.67% Drop From Highs? Read More »
   Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF  2021/12/15 13:00:00 investors Curis
   Curis (NASDAQ:CRIS) Stock Rating Lowered by Zacks Investment Research  2021/12/14 01:34:42 Dakota Financial News
Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday, reports. According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 キュ―リス CRIS Curis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)